Archived News
In August 2021 Finfeed changed from a website that covered ASX listed news to a website
that covered a select range of ASX
listed small cap Biotech stocks that we are personally
invested in: find out more.
The old Finfeed website, and all of the old articles are kept here for record keeping purposes.
VISIT NEW SITEPositive regulatory ramifications for CPH from US Marijuana Act
3 minute read
Creso Pharma Limited (ASX:CPH; FRA: 1X8) has advised that the US House of Representatives has passed the Marijuana Opportunity Reinvestment and Expungement (MORE) Act to remove cannabis for the US Controlled Substances Act.
The historic bill aims to erase certain federal convictions and essentially decriminalise cannabis for the first time on a national level.
The bill was passed in the lower chamber with 228 votes to 164 votes on Friday 4 December 2020 and will now move to the Senate.
This is a major milestone for the cannabis industry as legislation like the MORE Act is expected to encourage private investors and larger corporate entities that have been hesitant to become involved in the US cannabis industry due to federal prohibition.
The development leaves Creso Pharma very well positioned to capitalise on opportunities in the US market.
The company has an established global distribution network that will benefit from the ruling, as well as a leading Canadian subsidiary, Mernova Medicinal Inc. (Mernova) that can scale up operations to meet potential demand from the US market.
Mernova, which is Creso’s fully licenced 24,000 square foot cultivation growing facility is only 1700 miles from the US border, an ideal location to be able to cater to the Canadian and US market.
Having such close proximity to the US, Mernova will immediately benefit directly upon legalisation.
There is also substantial appetite for the group’s Swiss CBD products in the US, and management is exploring many initiatives to roll this out as soon as legalisation occurs.
There has been some extremely positive industry data released throughout the year, and the following chart indicates that the American marijuana business could increase to US$130 billion by 2024.
Creso’s shares surge following positive global regulatory developments
Creso co-founder and Director Boaz Wachtel highlighted the significance of this development, particularly on the back of last week’s news regarding regulatory shifts in the European Union in saying, “This is a historic ruling that will create significant growth opportunities in our burgeoning industry. It follows similar regulatory shifts in the European Union and from the United Nations that highlight public acceptance for cannabis and CBD-derived products is at an all-time high.
“Creso is very well positioned to capitalise on opportunities arising from the market in the USA.
“The company has a robust balance sheet, allowing it to progress near and medium term growth initiatives, as well as an established Canadian subsidiary in Mernova, which can be scaled up to address the US market.
“The appointment of Canopy Growth founder, Bruce Linton to Creso earlier this year will position Creso very strongly to take advantage of this new opportunity when it materialises.”
Such has been the quality of the newsflow that shares in Creso Pharma have increased more than threefold in less than a fortnight, and they are now trading at levels not seen since COVID sent our market tumbling at the start of the year.
Latest articles on Creso Pharma
More Commentary
Creso Pharma’s vital competitive advantages key to the future
06-07-2021
BDA finishes fiscal 2021 on a high
01-07-2021
Why CPH investors should care about The HighBrid Lab
24-06-2021
Creso and Red Light Holland to merge into The HighBrid Lab
17-06-2021S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
Publishers Notice
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain.